Menstrual cycle characteristics in fertile women from Greenland, Poland and Ukraine exposed to perfluorinated chemicals: A cross-sectional study

Human Reproduction

Volumn 29, Issue 2, 2014, Pages 359-367

  Lyngso J ^a   Ramlau Hansen, C H ^b   Hoyer B B ^a   Stovring H ^b   Bonde, J P ^c   Jonsson B A G ^d   Lindh, C H ^d   Pedersen, H S ^e   Ludwicki, J K ^f   Zviezdai, V ^g   Toft, G ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d LUND UNIVERSITY   (Sweden)

^e Centre for Arctic Environmental Medicine   (Greenland)

^f NATIONAL INSTITUTE OF HYGIENE   (Poland)

^g KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Menstrual cycle; PFOA; PFOS

Indexed keywords

PERFLUORO COMPOUND; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID;

ANALYTICAL PARAMETERS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CHEMICAL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; GREENLAND; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISORDER; OUTCOME ASSESSMENT; PARITY; POLAND; PREGNANT WOMAN; PROSPECTIVE STUDY; QUESTIONNAIRE; ROOM TEMPERATURE; SMOKING; TANDEM MASS SPECTROMETRY; UKRAINE;

MENSTRUAL CYCLE; PFOA; PFOS;

ALKANESULFONIC ACIDS; BODY MASS INDEX; CAPRYLATES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; FLUOROCARBONS; GREENLAND; HUMANS; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; POLAND; PRENATAL CARE; QUESTIONNAIRES; REGRESSION ANALYSIS; SMOKING; UKRAINE;

EID: 84893152983     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det390     Document Type: Article

References (54)

1. Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU, Needham LL, Goldman LR. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ Health Perspect 2007; 115:1670-1676.
2. Austin ME, Kasturi BS, Barber M, Kannan K, MohanKumar PS, MohanKumar SM. Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ Health Perspect 2003;111:1485-1489.
3. Belsey EM, Pinol AP. Menstrual bleeding patterns in untreated women. Task force on long-Acting systemic agents for fertility regulation. Contraception 1997;55:57-65.
4. Bonefeld-Jorgensen EC, Long M, Bossi R, Ayotte P, Asmund G, Kruger T, Ghisari M, Mulvad G, Kern P, Nzulumiki P. et al.: Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: A case-control study. Environ Health 2011;10:88.
5. Buck Louis GM, Rios LI, McLain A, Cooney MA, Kostyniak PJ, Sundaram R. Persistent organochlorine pollutants and menstrual cycle characteristics. Chemosphere 2011;85:1742-1748.
6. Butenhoff JL, Kennedy GL Jr, Frame SR, O'Connor JC, York RG. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology 2004;196:95-116.
7. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the U.S. population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons withNHANES 1999-2000. EnvironHealth Perspect 2007;115:1596-1602.
8. Case MT, York RG, Christian MS. Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. Int J Toxicol 2001;20:101-109.
9. Chen EC, Brzyski RG. Exercise and reproductive dysfunction. Fertil Steril 1999;71:1-6.
10. Cho SI, Damokosh AI, Ryan LM, Chen D, Hu YA, Smith TJ, Christiani DC, Xu X. Effects of exposure to organic solvents on menstrual cycle length. J Occup Environ Med 2001;43:567-575.
11. Collett ME, Wertenberger GE, Fiske VM. The effect of age upon the pattern of the menstrual cycle. Fertil Steril 1954;5:437-448.
12. Creinin MD, Keverline S, Meyn LA. How regular is regular? An analysis of menstrual cycle regularity. Contraception 2004;70:289-292.
13. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: A study within the Danish National Birth Cohort. Environ Health Perspect 2007;115:1677-1682.
14. Fei C, McLaughlin JK, Lipworth L, Olsen J. Maternal levels of perfluorinated chemicals and subfecundity. Hum Reprod 2009;24:1200-1205.
15. Fei C, Weinberg CR, Olsen J. Commentary: Perfluorinated chemicals and time to pregnancy: A link based on reverse causation? Epidemiology 2012; 23:264-266.
16. Fromel T, Knepper TP. Biodegradation of fluorinated alkyl substances. Rev Environ Contam Toxicol 2010;208:161-177.
17. Fruscalzo A, Bertozzi S, Londero AP, Biasioli A, Driul L, Kiesel L, Marchesoni D. Menstrual abnormalities and predisposition to pregnancy-related hypertensive disorders: A retrospective study. Gynecol Endocrinol 2010;26:445-450.
18. Giesy JP, Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol 2001;35:1339-1342.
19. Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women's health. Epidemiol Rev 1995;17:265-286.
20. Harlow SD, Lin X, Ho MJ. Analysis of menstrual diary data across the reproductive life span applicability of the bipartite model approach and the importance of within-woman variance. J Clin Epidemiol 2000;53: 722-733.
21. Hatch MC, Figa-Talamanca I, Salerno S.Work stress and menstrual patterns among American and Italian nurses. Scand J Work Environ Health 1999; 25:144-150.
22. Henry ND, Fair PA. Comparison of in vitro cytotoxicity, estrogenicity and anti-estrogenicity of triclosan, perfluorooctane sulfonate and perfluorooctanoic acid. J Appl Toxicol 2013;33:265-272.
23. Hornsby P, Wilcox AJ, Weinberg CR. Cigarette smoking and disturbances of menstrual function. Epidemiology 1998;9:193-198.
24. Jensen TK, Scheike T, Keiding N, Schaumburg I, Grandjean P. Fecundability in relation to body mass and menstrual cycle patterns. Epidemiology 1999; 10:422-428.
25. Jonsson BA, Rylander L, Lindh C, Rignell-Hydbom A, Giwercman A, Toft G, Pedersen HS, Ludwicki JK, Goralczyk K, ZvyezdayVet al. Inter-population variations in concentrations, determinants of and correlations between 2, 2′, 4, 4′, 5, 5′-hexachlorobiphenyl (CB-153) and 1, 1-dichloro-2, 2-bis (p-chlorophenyl)-ethylene (p, p′-DDE): A cross-sectional study of 3161 men and women from Inuit and European populations. Environ Health 2005;4:27.
26. Jukic AM, Weinberg CR, Wilcox AJ, McConnaughey DR, Hornsby P, Baird DD. Accuracy of reporting of menstrual cycle length. Am J Epidemiol 2008;167:25-33.
27. Juul S, KarmausW, Olsen J. Regional differences in waiting time to pregnancy: Pregnancy-based surveys from Denmark, France, Germany, Italy and Sweden. The European Infertility and Subfecundity Study Group. Hum Reprod 1999;14:1250-1254.
28. Kannan K, Corsolini S, Falandysz J, Fillmann G, Kumar KS, Loganathan BG, Mohd MA, Olivero J, Van WN, Yang JH. et al.: Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol 2004;38:4489-4495.
29. Knox SS, JacksonT, Javins B, Frisbee SJ, ShankarA, DucatmanAM. Implications of earlymenopause inwomenexposed toperfluorocarbons. J Clin Endocrinol Metab 2011;96:1747-1753.
30. Kolstad HA, Bonde JP, Hjollund NH, Jensen TK, Henriksen TB, Ernst E, Giwercman A, Skakkebaek NE, Olsen J. Menstrual cycle pattern and fertility: A prospective follow-up study of pregnancy and early embryonal loss in 295 couples who were planning their first pregnancy. Fertil Steril 1999;71:490-496.
31. Kraugerud M, Zimmer KE, Ropstad E, Verhaegen S. Perfluorinated compounds differentially affect steroidogenesis and viability in the human adrenocortical carcinoma (H295R) in vitro cell assay. Toxicol Lett 2011;205:62-68.
32. Lau C. Perfluoroalkyl acids: Recent research highlights. Reprod Toxicol 2012; 33:405-409.
33. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroalkyl acids: A review of monitoring and toxicological findings. Toxicol Sci 2007; 99:366-394.
34. Lindh CH, Rylander L, Toft G, Axmon A, Rignell-Hydbom A, Giwercman A, Pedersen HS, Goalczyk K, Ludwicki JK, Zvyezday V. et al.: Blood serum concentrations of perfluorinated compounds in men from Greenlandic Inuit and European populations. Chemosphere 2012;88:1269-1275.
35. Luebker DJ, Case MT, York RG, Moore JA, Hansen KJ, Butenhoff JL. Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology 2005;215:126-148.
36. McLain AC, Lum KJ, Sundaram R. A joint mixed effects dispersion model for menstrual cycle length and time-To-pregnancy. Biometrics 2012;68:648-656.
37. Mumford SL, Schisterman EF, Gaskins AJ, Pollack AZ, Perkins NJ, Whitcomb BW, Ye A, Wactawski-Wende J. Realignment and multiple imputation of longitudinal data: An application to menstrual cycle data. Paediatr Perinat Epidemiol 2011;25:448-459.
38. Mumford SL, Steiner AZ, Pollack AZ, Perkins NJ, Filiberto AC, Albert PS, Mattison DR, Wactawski-Wende J, Schisterman EF. The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. J Clin Endocrinol Metab 2012;97:e1871-1879.
39. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, Zobel LR. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007;115:1298-1305.
40. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-38.
41. Rowland AS, Baird DD, Long S, Wegienka G, Harlow SD, Alavanja M, Sandler DP. Influence of medical conditions and lifestyle factors on the menstrual cycle. Epidemiology 2002;13:668-674.
42. Rubin DB, Little RJ. Multiple Imputation for Nonresponse in Surveys. New York, USA: JohnWiley & sons, 1987.
43. SmallCM, Manatunga AK, MarcusM.Validity of self-reportedmenstrual cycle length. Ann Epidemiol 2007;17:163-170.
44. Small CM, Manatunga AK, Klein M, Dominguez CE, Feigelson HS, McChesney R, Marcus M. Menstrual cycle variability and the likelihood of achieving pregnancy. Rev Environ Health 2010;25:369-378.
45. Steiner MJ, Hertz-Picciotto I, Taylor D, Schoenbach V, Wheeless A. Retrospective vs. prospective coital frequency and menstrual cycle length in a contraceptive effectiveness trial. Ann Epidemiol 2001;11:428-433.
46. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, KenwardMG, WoodAM, Carpenter Jr. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. Br Med J 2009;338:b2393.
47. Toft G, Axmon A, Giwercman A, Thulstrup AM, Rignell-Hydbom A, Pedersen HS, Ludwicki JK, Zvyezday V, Zinchuk A, Spano M. et al.: Fertility in four regions spanning large contrasts in serum levels of widespread persistent organochlorines: A cross-sectional study. Environ Health 2005;4:26.
48. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967;12:77-126.
49. Van Eijkeren MA, Christiaens GC, Sixma JJ, Haspels AA. Menorrhagia: A review. Obstet Gynecol Surv 1989;44:421-429.
50. Vested A, Ramlau-Hansen CH, Olsen SF, Bonde JP, Kristensen SL, Halldorsson TI, Becher G, Haug LS, Ernst EH, Toft G. Associations of in utero exposure to perfluorinated alkyl acids with human semen quality and reproductive hormones in adult men. Environ Health Perspect 2013; 121:453-458.
51. Vestergaard S, Nielsen F, Andersson AM, Hjollund NH, Grandjean P, Andersen HR, Jensen TK. Association between perfluorinated compounds and time to pregnancy in a prospective cohort of Danish couples attempting to conceive. Hum Reprod 2012;27:873-880.
52. Whitworth KW, Haug LS, Baird DD, Becher G, Hoppin JA, Skjaerven R, Thomsen C, Eggesbo M, Travlos G, Wilson R. et al.: Perfluorinated compounds and subfecundity in pregnant women. Epidemiology 2012; 23:257-263.
53. Wolf CJ, Fenton SE, Schmid JE, Calafat AM, Kuklenyik Z, Bryant XA, Thibodeaux J, Das KP, White SS, Lau CS. et al.: Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol Sci 2007;95:462-473.
54. YangCY, Huang TS, Lin KC, KuoP, Tsai PC, GuoYL. Menstrual effectsamong women exposed to polychlorinated biphenyls and dibenzofurans. Environ Res 2011;111:288-294.